Systemic sclerosis associated myopathy

Benjamin Chaigne; Sarah Léonard-Louis; Luc Mouthon

doi:10.1016/j.autrev.2022.103261

Systemic sclerosis associated myopathy

Autoimmun Rev. 2023 Feb;22(2):103261. doi: 10.1016/j.autrev.2022.103261. Epub 2022 Dec 20.

Authors

Benjamin Chaigne¹, Sarah Léonard-Louis², Luc Mouthon³

Affiliations

¹ Service de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), France; APHP-CUP, Hôpital Cochin, Université de Paris, F-75014 Paris, France. Electronic address: [email protected].
² Clinical Neurophysiology, Pitié-Salpétrière Hospital, Paris, France.
³ Service de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), France; APHP-CUP, Hôpital Cochin, Université de Paris, F-75014 Paris, France.

PMID: 36549354
DOI: 10.1016/j.autrev.2022.103261

Abstract

Scleroderma associated myopathy (SScAM) is a common but heterogeneous musculoskeletal manifestation of systemic sclerosis (SSc) for which there is still no clear definition. Still, SScAM is associated with disability, poor quality of life and mortality. This review discusses the most updated literature of SScAM including clinical and antibody associations, recent updates on histopathological findings, prognosis and treatment.

Keywords: Fibrosis; Myopathy; Myositis; Prognosis; Systemic sclerosis; Systemic sclerosis associated myopathy; Vasculopathy.

Publication types

Review

MeSH terms

Humans
Muscular Diseases* / complications
Muscular Diseases* / therapy
Prognosis
Quality of Life
Scleroderma, Localized* / complications
Scleroderma, Systemic* / complications
Scleroderma, Systemic* / therapy